Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOC237 in advanced solid tumors
NCT05895825Phase 1Recruiting
- Sponsor
- Shanghai Yiteng Jingang Bio-pharmaceutical Technology
- Start
- Jul 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of EOC237 in solid tumor (advanced stage) (3 arms), sponsored by Shanghai Yiteng Jingang Bio-pharmaceutical Technology. Primary endpoints: Proportion of subjects with dose-limiting toxicity at 28 days, Maximum Tolerated Dose at 3 years and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
EOC237
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05895825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895825.